Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127880241 | 12788024 | 1 | I | 20160823 | 20160928 | 20160928 | EXP | US-ROCHE-1835329 | ROCHE | 56.00 | YR | F | Y | 40.00000 | KG | 20160928 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127880241 | 12788024 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 1 | 125085 | 880 | MG | SOLUTION FOR INFUSION | |||||||
| 127880241 | 12788024 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 3 | 125085 | 848 | MG | SOLUTION FOR INFUSION | |||||||
| 127880241 | 12788024 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | CYCLE 5?THE THERAPY DISCONTINUED AFTER CYCLE 5 DUE TO AN UNSPECIFIED REASON | 125085 | 820 | MG | SOLUTION FOR INFUSION | |||||||
| 127880241 | 12788024 | 4 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE 1 | 0 | 75 | MG | ||||||||
| 127880241 | 12788024 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE 2 | 0 | 100 | MG | ||||||||
| 127880241 | 12788024 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE 6 | 0 | 80 | MG | ||||||||
| 127880241 | 12788024 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE 7?THERAPY DISCONTINUED AFTER CYCLE 7 DUE TO ADVERSE EVNETS/SIDE EFFECTS/COMPLICATIONS | 0 | 60 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127880241 | 12788024 | 1 | Carcinoid tumour |
| 127880241 | 12788024 | 4 | Carcinoid tumour |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127880241 | 12788024 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127880241 | 12788024 | Blood bilirubin increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127880241 | 12788024 | 1 | 20091222 | 0 | ||
| 127880241 | 12788024 | 2 | 20091222 | 0 | ||
| 127880241 | 12788024 | 3 | 20100413 | 0 | ||
| 127880241 | 12788024 | 4 | 20091222 | 0 | ||
| 127880241 | 12788024 | 5 | 20100119 | 0 | ||
| 127880241 | 12788024 | 6 | 20100601 | 0 | ||
| 127880241 | 12788024 | 7 | 20100601 | 20100713 | 0 |